BioSpace News Archive

Biotheryx, Inc. today announced the appointment of Tracy Lawhon, J.D., as Chief Development Officer (CDO).

Compugen Ltd. announced today that the Japan Patent Office has granted Compugen a new composition of matter and use patent covering its potentially first-in-class anti-PVRIG, COM701 and backup anti-PVRIG antibodies.

Tessera Therapeutics, the biotechnology company pioneering GENE WRITING™ technology, today announced the appointment of Anne-Virginie Eggimann, M.Sc. as Chief Regulatory Officer (CRO) responsible for leading U.S. and global regulatory science and program.

Ayala Pharmaceuticals, Inc. announced that data on the efficacy and tolerability of investigational new drug AL102 from Part A of the Phase 2/3 RINGSIDE study will be presented in an oral presentation at the European Society for Medical Oncology Congress, to take place September 8-13, 2022 in Paris, France.

Daré Bioscience, Inc. today announced that it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol monolaurate (GML) intravaginally for a variety of vaginal health conditions including bacterial, fungal, and viral infections.

Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601.

Oncocyte Corporation today announces the peer-reviewed publication evaluating the performance of DetermaIO™ in metastatic urothelial (bladder) cancer treated with the immune checkpoint inhibitor (ICI), Tencentriq ® (atezolizumab).

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, announced the National Screening Laboratory of Sanquin Blood Supply Foundation, Department Research & Labservices, headquartered in Amsterdam, the Netherlands has joined MosaiQ Innovator’s Circle.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis (NASH) have been published in JHEP Reports.

Pressure BioSciences, Inc. today announced the Company’s agreement to team with science-driven skincare industry leader Dr. Adrienne Denese, M.D., Ph.D.